Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in relapsed or refractory Waldenström macroglobulinemia in Chinese patients
CTR20191968Phase 4Completed
- Sponsor
- Pharmacyclics
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ibrutinib in Waldenström macroglobulinemia (WM), sponsored by Pharmacyclics. Started Oct 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on CTR20191968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191968.